Search

Background: Previously, a new dichotomous outcome was developed, calculated as 55% reduction in the International Hidradenitis Suppurativa 4 (IHS4-55) score. It was validated in datasets of adalimumab and placebo-treated HS patients. External validation is an important aspect of clinical outcomes. Objectives: We aimed to externally validate the novel dichotomous IHS4-55 in a non-biologic treated dataset of HS patients. Methods: Data from a previously published European-wide prospective clinical study of antibiotic treatment of HS patients were used to assess the association of IHS4-55 achievement with individual reduction in inflammatory nodules, abscesses, and draining tunnels. Moreover, the associations between IHS4-55 positivity and achievement of the minimal clinically important differences (MCIDs) for Dermatology Life Quality Index (DLQI), Numerical Rating Scale (NRS) Pain, and NRS Pruritus were analyzed. Results: Data were obtained from 283 individual patients, of which 36.4% (103/283) were treated with clindamycin and rifampicin and 63.6% (180/283) with tetracyclines for 12 weeks. Achievers of the IHS4-55 demonstrated a significant reduction the counts of inflammatory nodules, abscesses, and draining tunnels (all p < 0.001). Additionally, IHS4-55 achievers had an odds ratio for achieving the MCID of DLQI, NRS Pain, and NRS Pruritus of 2.16 (95% CI 1.28-3.65, p < 0.01), 1.79 (95% CI 1.10-2.91, p < 0.05), and 1.95 (95% CI 1.18-3.22, p < 0.01), respectively. Conclusions: This study shows the external validity of the novel IHS4-55 by demonstrating a significant association between IHS4-55 achievement and a reduction in inflammatory lesion counts as well as achievement of MCIDs for DLQI, NRS Pain, and NRS Pruritus in an antibiotic-treated cohort. These findings support the use of the IHS4-55 as a novel primary outcome measure in clinical trials.

Anne-Claire Fougerousse,1 François Maccari,1,2 Philippe Guillem,3 Ziad Reguiai4 On behalf of the GEM ResoVerneuil1Dermatology Department, Military Teaching Hospital Bégin, Saint Mandé, France; 2Dermatology, Private Practice, Saint-Maur-des-Fossés, France; 3Visceral Surgery department, Clinique du Val d’Ouest, Ecully, France; 4Dermatology Department, Polyclinique Courlancy-Bezannes, Reims, FranceCorrespondence: Anne-Claire Fougerousse, Dermatology department, Military Teaching Hospital Bégin, Saint Mandé, France, Tel +1 43 98 50 00, Email ac.fougerousse@gmail.comPurpose: Antibiotics are used for hidradenitis suppurativa’s management with limited evidence. Choice of antibiotics is based on small randomized controlled trial or open case-series.Patients and Methods: We performed a practice survey in Resoverneuil, a French network of physicians treating hidradenitis suppurativa, to identify the antibiotic strategy according to the Hurley stage. Online questionnaire was sent to all members of ResoVerneuil between January and February 2021.Results: In total, 108 physicians answered the survey: 37.6% were hospital based, 34.6% had a private practice and 27.8% a mixed practice, and 13.8% had a dedicated consultation for hidradenitis suppurativa. Sixty-three physicians reported seeing fewer than 5 patients with hidradenitis suppurativa per month; 29 seeing 5 to 15 patients per month; and 9 seeing more than 15 patients per month. More than 90% declared prescribing antibiotics for flares in Hurley 1 and 2 stages, and 83% in Hurley 3 stages, mostly amoxicillin-clavulanic acid and pristinamycin. Of these physicians, 29.7% declared prescribing a background antibiotic therapy for Hurley 1 stage with less than 4 flares per year, and more than 75% for Hurley 1 stage with more than 4 flares per year, Hurley 2 and Hurley 3 stages; mostly cyclins, combination of rifampicin and clindamycin and sulfamethoxazole-trimethoprim.Conclusion: This survey underlines the heterogeneity in

Jean-Luc Perrot,1,2 François Maccari,2,3 Philippe Guillem,2,4– 6 Anne-Claire Fougerousse,2,7 Aude Nassif,2,8 Nathalie Beneton,2,9 Elisa Cinotti,2,10 Céline Girard,2,11 Raphaelle Binois,2,12 Ziad Reguiaï2,13 On behalf of the ResoVerneuil group1Department of Dermatology, University Hospital of Saint-Etienne, Saint-Etienne, France; 2ResoVerneuil, Ville, France; 3Private Office, La Varenne St Hilaire, France; 4Service de chirurgie adulte, clinique du Val-d’Ouest, Ecully, 69130, France; 5European Hidradenitis Suppurativa Foundation, Dessau, Germany; 6Groupe de Recherche En proctologie de la Société Nationale Francophone de Colo-Proctologie, Paris, France; 7Military Teaching Hospital Bégin, Saint Mandé, France; 8Centre Médical de l’Institut Pasteur, Paris, 75015, France; 9Dermatology Department, Centre Hospitalier du Mans, Le Mans, France; 10Department of Medical, Dermatology Unit, Surgical and Neuro.Sciences, University of Siena, Siena, Italy; 11Dermatology Department, Centre Hospitalier Universitaire de Montpellier, Montpellier, France; 12Dermatology Department, Centre Hospitalier Régional d’Orléans, Orléans Cedex, 45067, France; 13Service de dermatologie, polyclinique Courlancy, Reims, 51100, FranceCorrespondence: Jean-Luc Perrot, Department of Dermatology, University Hospital of Saint-Etienne, Saint-Etienne, France, Email j.luc.perrot@chu-st-etienne.frPurpose: Hidradenitis suppurativa (HS) is an inflammatory skin disease characterized by recurrent or chronic painful and suppurating lesions in the apocrine gland-bearing regions. The lack of knowledge about HS and its extremely heterogeneous clinical presentation, in terms of both lesion appearance and sites of involvement, frequently delay its diagnosis for several years. Objectives: in this study, using the latent class analysis, it was demonstrated that severit

SCOPUS: le.j, info:eu-repo/semantics/published

SCOPUS: le.j, info:eu-repo/semantics/published

Hidradenitis suppurativa (HS) rarely affects pediatric patients. The literature on pediatric HS patients is scarce. This is a cross-sectional study based on case note review or interviews and clinical examination of 140 pediatric patients undergoing secondary or tertiary level care. Patients were predominantly female (75.5%, n = 105) with a median age of 16. 39% reported 1st-degree relative with HS. Median BMI percentile was 88, and 11% were smokers (n = 15). Median modified Sartorius score was 8.5. Notable comorbidities found were acne (32.8%, n = 45), hirsutism (19.3%, n = 27), and pilonidal cysts (16.4%, n = 23). Resorcinol (n = 27) and clindamycin (n = 25) were the most frequently used topical treatments. Patients were treated with tetracycline (n = 32), or oral clindamycin and rifampicin in combination (n = 29). Surgical excision was performed in 18 patients, deroofing in five and incision in seven patients. Obesity seemed to be prominent in the pediatric population and correlated to parent BMI, suggesting a potential for preventive measures for the family. Disease management appeared to be similar to that of adult HS, bearing in mind that the younger the patient, the milder the disease in majority of cases.

SCOPUS: le.j, info:eu-repo/semantics/published

The 14 authors of the first review article on hidradenitis suppurativa (HS) pathogenesis published 2008 in EXPERIMENTAL DERMATOLOGY cumulating from the 1st International Hidradenitis Suppurativa Research Symposium held March 30-April 2, 2006 in Dessau, Germany with 33 participants were prophetic when they wrote "Hopefully, this heralds a welcome new tradition: to get to the molecular heart of HS pathogenesis, which can only be achieved by a renaissance of solid basic HS research, as the key to developing more effective HS therapy." (Kurzen et al. What causes hidradenitis suppurativa? Exp Dermatol 2008;17:455). Fifteen years later, there is no doubt that the desired renaissance of solid basic HS research is progressing with rapid steps and that HS has developed deep roots among inflammatory diseases in Dermatology and beyond, recognized as "the only inflammatory skin disease than can be healed". This anniversary article of 43 research-performing authors from all around the globe in the official journal of the European Hidradenitis Suppurativa Foundation e.V. (EHSF e.V.) and the Hidradenitis Suppurativa Foundation, Inc (HSF USA) summarizes the evidence of the intense HS clinical and experimental research during the last 15 years in all aspects of the disease and provides information of the developments to come in the near future., SCOPUS: re.j, info:eu-repo/semantics/published

The factors that determine whether an area of the body will be affected by hidradenitis suppurativa (HS) are unknown., info:eu-repo/semantics/published

info:eu-repo/semantics/published

info:eu-repo/semantics/published

Background: Hidradenitis suppurativa (HS), also referred to as acne inversa, is a debilitating skin disease characterized by inflammatory nodules, chronic abscesses and tunnels (fistulae and sinuses). The association with pilonidal sinus disease (PSD) is frequently reported but not well documented. Objectives: To determine the prevalence and characteristics of inflammatory skin lesions located in the intergluteal fold (IGF) of patients with HS. Methods: This was an international multicentre retrospective cross-sectional study based on data collection from a large cohort of patients with HS with and without histopathology. Results From a total of 2465 patients with HS included in the study, 661 (27%) reported lesions in the IGF. These patients were significantly more often smokers and had more severe HS. Of the 238 patients with an available clinical diagnosis, intergluteal-HS (IG-HS) was diagnosed in 52 patients (22%) and PSD was diagnosed in 186 patients (78%). IG-HS was associated with the localization of HS in the proximity of the IGF, including the buttocks, genitals and the anus. There was a possibility of misclassification bias in this study as a clinical/image-based diagnosis or histopathology of the IGF lesions was not always available. Conclusions: The high prevalence of PSD suggests a strong link between both entities. Therefore, it may be useful to identify common pathophysiological mechanisms and develop common therapeutic strategies., SCOPUS: ar.j, info:eu-repo/semantics/published